中国新生儿协作网2019—2023年胎龄<32周早产儿呼吸窘迫综合征救治情况与结局趋势
该横断面研究基于中国新生儿协作网(CHNN)2019—2023年收治的30 869例出生胎龄<32周呼吸窘迫综合征(RDS)早产儿,分析其救治情况及5年变化趋势。结果显示RDS患病率逐年增加(从73.8%升至86.0%,P<0.001),病死率逐年下降(4.6%,P=0.005),但支气管肺发育不良(BPD)发生率及死亡或BPD复合发生率逐年增加(均P<0.001)。母产前激素及产房无创呼气末正压通气应用率逐年增加,但足疗程产前激素应用率逐年下降,围生期管理仍有待规范。
要点
- 2019—2023年CHNN胎龄<32周RDS早产儿患病率逐年增加,从73.8%升至86.0%(P<0.001)。
- RDS患儿住院病死率4.6%且逐年下降(P=0.005),但BPD发生率35.0%及死亡或BPD复合发生率36.4%均逐年增加(均P<0.001)。
- 母产前激素及产房无创呼气末正压通气应用率逐年增加(均P<0.001),但足疗程产前激素应用率仅64.6%且逐年下降。
核心结论
- 2019—2023年CHNN出生胎龄<32周早产儿RDS患病率逐年增加,病死率逐年下降,但BPD发生率及死亡或BPD复合发生率逐年增加。
- 母产前激素及产房无创呼气末正压通气应用率逐年增加,但足疗程产前激素应用率逐年下降,围生期管理仍有待规范和提高。
研究设计与样本
- 2024年11月至2025年1月基于CHNN极早产儿和超早产儿队列进行的横断面研究。
- 纳入2019—2023年CHNN各单位收治的入院时出生≤1 d的出生胎龄<32周RDS患儿30 869例。
- 采集基本情况、围生期管理、生后7 d内并发症及住院结局,按入院年份分组。
- 采用Cochran-Armitage趋势分析、线性回归模型和中位数回归模型分析各临床特征随年份的变化趋势。
主要发现
- 30 869例RDS患儿出生胎龄28.9(27.1,30.7)周,出生体重1 259(932,1 586)g,男性占56.5%(17 363/30 757)。
- 2019—2023年RDS患病率分别为73.8%(5 503/7 461)、74.5%(5 490/7 368)、79.8%(5 884/7 372)、81.6%(6 435/7 889)、86.0%(7 557/8 789),呈逐年增加趋势(P<0.001)。
- 肺表面活性物质治疗率72.4%(22 359/30 869),5年间波动于71.2%(5 381/7 557)~74.3%(4 089/5 503)。
- 母产前激素应用率82.3%(24 357/29 597),产房无创呼气末正压通气应用率23.6%(7 218/30 565),生后7 d内气胸发生率1.3%(393/30 846),吸入一氧化氮应用率1.4%(436/30 869),均呈逐年增加趋势(均P<0.001)。
- 足疗程母产前激素应用率64.6%(14 458/22 382),生后7 d内自动出院率5.3%(1 635/30 869),生后7 d内病死率2.7%(724/26 803),均呈逐年下降趋势(均P<0.05)。
关键数值与推荐
- RDS患儿住院病死率4.6%(1 228/26 803),呈逐年下降趋势(P=0.005)。
- 支气管肺发育不良(BPD)发生率35.0%(9 417/26 919),死亡或BPD复合发生率36.4%(9 763/26 803),均呈逐年增加趋势(均P<0.001)。
临床怎么用
- 关注胎龄<32周RDS早产儿患病率逐年增加的趋势,加强围生期管理。
- 尽管病死率下降,但BPD及死亡或BPD复合发生率增加,需重视BPD的预防与管理。
- 提高足疗程产前激素的应用率,并继续推广产房无创呼气末正压通气支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the current status and trends in the clinical management and outcomes of respiratory distress syndrome (RDS) in preterm infants <32 weeks' gestation admitted to the Chinese Neonatal Network (CHNN) from 2019 to 2023. Methods: A cross-sectional study was conducted from November 2024 to January 2025 using the CHNN cohort of very preterm and extremely preterm infants. A total of 30 869 RDS infants with gestational age <32 weeks were admitted within 1 day after birth to CHNN centers from 2019 to 2023. Data on demographics, perinatal management, early complications within 7 days of age, and in-hospital outcomes were collected. Yearly groups were defined by admission year. Trends by year were evaluated by Cochran-Armitage trend test, linear regression model and median regression model. Results: The gestational age at birth of 30 869 RDS infant was 28.9 (27.1, 30.7) weeks and the birth weight was 1 259 (932, 1 586) g. Males account for 56.5% (17 363/30 757). From 2019 to 2023, the prevalence of RDS was 73.8% (5 503/7 461), 74.5% (5 490/7 368), 79.8% (5 884/7 372), 81.6% (6 435/7 889), and 86.0% (7 557/8 789), respectively, showing an increasing trend year by year (P<0.001). The overall rate of pulmonary surfactant administration was 72.4% (22 359/30 869), fluctuating between 71.2% (5 381/7 557) and 74.3% (4 089/5 503) over the 5-year period. Antenatal corticosteroids were administered to 82.3% (24 357/29 597) mothers of RDS infants and 23.6% (7 218/30 565) RDS infants received noninvasive positive end-expiratory pressure support in the delivery room, both showing a increasing trend over the 5 years (both P<0.001). The incidence of pneumothorax and the use rate of inhaled nitric oxide within 7 days of age were 1.3% (393/30 846) and 1.4% (436/30 869), respectively, both showing increasing trends over the 5 years (both P<0.001). The rate of complete course of antenatal corticosteroids administration was 64.6% (14 458/22 382), the rates of discharge against medical advice and mortality within 7 days of age were 5.3% (1 635/30 869) and 2.7% (724/26 803), respectively, all showing a decreasing trend over time (all P<0.05). Regarding in-hospital outcomes, mortality rate of RDS infants was 4.6% (1 228/26 803), showing a downward trend year by year (P=0.005). The incidence of bronchopulmonary dysplasia (BPD) was 35.0% (9 417/26 919), and the combined incidence of death or BPD was 36.4% (9 763/26 803), both showing an increasing trend year by year (both P<0.001). Conclusions: RDS prevalence increased annually in preterm infants <32 weeks' gestation from 2019 to 2023, with declining mortality but rising BPD rates. While antenatal steroid use and noninvasive positive end-expiratory pressure support application improved, full-course antenatal steroid compliance decreased. These findings highlight the need for standardized perinatal management protocols to improve the clinical management of RDS. 目的: 分析2019—2023年中国新生儿协作网(CHNN)出生胎龄<32周早产儿呼吸窘迫综合征(RDS)的救治情况及5年变化趋势。 方法: 2024年11月至2025年1月进行基于CHNN极早产儿和超早产儿队列的横断面研究,纳入2019—2023年CHNN各单位收治的入院时出生≤1 d的出生胎龄<32周RDS患儿30 869例。采集患儿的基本情况、围生期管理、生后7 d内并发症及住院结局。根据入院年份分组,采用Cochran-Armitage趋势分析、线性回归模型和中位数回归模型分析各临床特征随年份的变化趋势。 结果: 30 869例出生胎龄<32周RDS患儿出生胎龄28.9(27.1,30.7)周,出生体重1 259(932,1 586)g;男性占56.5%(17 363/30 757)。2019—2023年RDS患病率分别为73.8%(5 503/7 461)、74.5%(5 490/7 368)、79.8%(5 884/7 372)、81.6%(6 435/7 889)、86.0%(7 557/8 789),呈逐年增加趋势(P<0.001)。肺表面活性物质治疗率72.4%(22 359/30 869),5年间波动于71.2%(5 381/7 557)~74.3%(4 089/5 503)。母产前激素、产房无创呼气末正压通气应用率分别为82.3%(24 357/29 597)和23.6%(7 218/30 565),生后7 d内气胸发生率、吸入一氧化氮应用率分别为1.3%(393/30 846)和1.4%(436/30 869),均呈逐年增加趋势(均P<0.001);足疗程母产前激素应用率为64.6%(14 458/22 382),生后7 d内自动出院率和病死率分别为5.3%(1 635/30 869)和2.7%(724/26 803),均呈逐年下降趋势(均P<0.05)。住院结局方面,RDS患儿病死率4.6%(1 228/26 803),呈逐年下降趋势(P=0.005);支气管肺发育不良发生率35.0%(9 417/26 919),死亡或BPD发生率36.4%(9 763/26 803),均呈逐年增加趋势(均P<0.001)。 结论: 2019—2023年CHNN出生胎龄<32周早产儿RDS患病率逐年增加,病死率呈逐年下降趋势,母产前激素应用及产房无创呼气末正压通气应用率呈逐年增加趋势,但足疗程产前激素呈逐年下降趋势,围生期管理仍有待规范和提高。.
引用
- He Y, Chen X, Zu LJ, et al. [Clinical management and outcomes of respiratory distress syndrome in preterm infants <32 weeks' gestation from the Chinese Neonatal Network from 2019 to 2023]. Zhonghua Er Ke Za Zhi. 2025. PMID: 40692458. doi:10.3760/cma.j.cn112140-20250221-00138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。